Can I Take Omega-3 (EPA/DHA) with Tresiba (Insulin Degludec)?

Insulin degludec, marketed as Tresiba, is a long-acting basal insulin approved by the FDA to help manage blood sugar levels in both adults and children diagnosed with type 1 or type 2 diabetes. Fish oil supplements containing omega-3 fatty acids like EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are sold over-the-counter, though prescription versions including icosapentaenoic acid (Vascepa) and omega-3-acid ethyl esters (Lovaza) are FDA-approved specifically for treating severe hypertriglyceridemia and reducing cardiovascular risk. This article focuses on over-the-counter fish oil supplements rather than prescription omega-3 formulations, although the underlying pharmacology remains consistent across both forms.

There is no known pharmacokinetic interaction between omega-3 supplementation and insulin degludec. The two do not compete for the same absorption, protein-binding, or clearance pathways. The relevant concern is pharmacodynamic: at higher intakes, omega-3s can modestly affect glucose handling and add to the antiplatelet effect that insulin itself already produces, which matters mainly for patients who are also on anticoagulants or antiplatelet drugs. For a person on stable Tresiba therapy taking a typical over-the-counter dose of 1 to 2 g/day combined EPA+DHA, the added risk appears small, but it has not been directly studied in insulin degludec users specifically, so routine glucose monitoring after starting or changing dose is the reasonable safeguard rather than an assumption of zero effect.

Why this is a pharmacodynamic question, not a pharmacokinetic one

A pharmacokinetic interaction changes how much of a drug reaches the bloodstream or how quickly it is cleared. A pharmacodynamic interaction changes the drug's effect without changing its blood level. Insulin degludec is absorbed from a subcutaneous depot where it forms multi-hexamer chains that slowly release monomeric insulin into circulation, a process governed by zinc coordination chemistry and albumin binding rather than by lipid metabolism. Its clearance depends mainly on insulin-degrading enzyme in the liver, kidney, and muscle. EPA and DHA are handled through entirely different pathways: beta-oxidation and desaturase/elongase enzyme systems, not the cytochrome P450 enzymes that account for most drug-supplement interactions.

Because these pathways do not overlap, omega-3 supplementation is not expected to change insulin degludec's absorption, half-life, or duration of action. This is a mechanistic inference based on known pharmacology rather than a finding from a dedicated interaction trial in Tresiba users, and no such trial is cited here because none was located in the sources reviewed for this article.

What omega-3s plausibly do to blood glucose

The glucose effect of fish oil in people with diabetes has been debated for decades, and the picture has shifted with better trial design.

Older, smaller trials using very high doses (5 to 10 g/day) reported modest increases in fasting glucose. More recent evidence at lower and more typical doses (2 to 4 g/day) has generally found little to no significant change in HbA1c or fasting glucose in people with type 2 diabetes. The Standards of Care in Diabetes published annually by the American Diabetes Association takes the position that omega-3 fatty acids do not improve glycemic control but may offer cardiovascular benefit in patients at elevated cardiovascular risk, and does not list omega-3 supplementation as contraindicated with any insulin formulation, including insulin degludec (ADA Standards of Care).

The REDUCE-IT trial tested prescription-strength EPA (4 g/day icosapentaenoic acid, marketed as Vascepa) in statin-treated patients at elevated cardiovascular risk, a population that included many people with diabetes, and reported a substantial reduction in major cardiovascular events without describing clinically meaningful glucose deterioration as a limiting factor (Bhatt et al., NEJM 2019). That trial evaluated cardiovascular outcomes, not insulin dosing or hypoglycemia rates, so it should not be read as direct evidence about how EPA behaves specifically in insulin degludec users; it establishes that high-dose EPA is not obviously glucose-destabilizing in a large diabetic-inclusive population, nothing more precise than that.

A note on the underlying trial data behind the older glucose-worsening and neutral-effect findings: several of the specific study citations commonly attached to this claim (older meta-analyses and Cochrane reviews) could not be independently verified against the primary literature for this draft. The general direction described above, that higher historical doses showed more glucose signal than modern lower doses, is consistent with what is publicly reported about this literature, but exact effect sizes (for example, a specific mmol/L or percentage HbA1c change) should be confirmed against the primary paper before being stated as a precise figure in patient-facing material.

Type 1 versus type 2 diabetes

In type 1 diabetes, there is no endogenous insulin production, so any improvement in peripheral insulin sensitivity from omega-3s would only translate into lower glucose if the exogenous Tresiba dose is adjusted accordingly. A patient whose sensitivity genuinely improves after starting omega-3s could see more hypoglycemia over time if the dose is not reduced, though this would be expected to develop gradually rather than suddenly.

In type 2 diabetes, especially with underlying insulin resistance, there is a plausible mechanism (PPAR-alpha and PPAR-gamma activation, altered adipokine signaling) by which omega-3s could modestly improve insulin sensitivity, but the clinical effect size at typical OTC doses appears small for most patients.

The antiplatelet question, which matters more than most patients expect

Insulin and omega-3 fatty acids each independently reduce platelet aggregation through separate mechanisms: insulin via the PI3K signaling pathway, and EPA/DHA by displacing arachidonic acid in platelet membranes and shifting thromboxane production toward a less active form. Neither effect alone is typically dangerous, but they can be additive, and the combination has not been studied as a dedicated interaction in people using insulin degludec specifically.

This matters most for patients who are also taking aspirin, warfarin, clopidogrel, or another anticoagulant or antiplatelet drug. The FDA prescribing information for prescription-strength EPA products instructs monitoring for bleeding in patients on anticoagulant or antiplatelet therapy; that labeling does not name insulin degludec, but the underlying platelet-function principle is the same regardless of what is causing the baseline antiplatelet state (verify current label language directly at FDA.gov before citing a specific warning, since label text is revised over time).

At standard OTC doses of 1 to 2 g/day EPA+DHA, spontaneous bleeding from the combination with insulin alone, in a patient not on any other antithrombotic drug, would be unexpected. At prescription-strength doses of 4 g/day, a full medication review before starting is reasonable regardless of what insulin the patient uses.

What this means for dosing decisions

No dose-separation window between an omega-3 supplement and a Tresiba injection is pharmacologically necessary, because the interaction is not one of competing for absorption at the same site or time. Take omega-3 supplements as labeled, generally with meals for better absorption.

Dose level is the more important variable than timing:

• 1 to 2 g/day EPA+DHA (typical OTC fish oil): lowest-risk range described in the literature reviewed here. Routine self-monitoring of blood glucose after starting is a reasonable precaution rather than a required protocol.
• 2 to 3 g/day: triglyceride-lowering becomes more pronounced; a one-time review of the medication list with a prescriber or pharmacist before committing to this dose long-term is reasonable.
• 4 g/day prescription-strength (Vascepa, Lovaza): these are FDA-approved prescription drugs used for severe hypertriglyceridemia or cardiovascular risk reduction, not OTC supplement decisions, and starting them should already involve a prescriber. The relevant product labeling should be reviewed directly for glucose and bleeding monitoring guidance current as of the date it is checked.

Evidence-status interaction assessment

Special situations that warrant closer attention

Chronic kidney disease. Reduced kidney function can slow insulin clearance and raise hypoglycemia risk independent of any supplement. Whether omega-3 supplementation changes this risk meaningfully has not been well studied; closer glucose monitoring is a reasonable precaution in this group regardless of omega-3 use.

Pregnancy. Omega-3 supplementation during pregnancy has recognized potential benefits for fetal neurodevelopment, and obstetric guidance on this generally supports appropriate omega-3 intake in pregnancy; insulin requirements also change substantially across trimesters for reasons unrelated to supplement use. Any glucose instability during pregnancy in a patient on Tresiba should go to the treating obstetric and endocrinology team promptly rather than being managed through self-adjustment.

Concurrent antiplatelet or anticoagulant therapy. This is the subgroup with the most plausible added risk from combining omega-3s with insulin therapy. The three-way combination of an anticoagulant, an antiplatelet-dose omega-3 product, and insulin has not been studied as a dedicated interaction, so a documented benefit-risk conversation with the prescriber before starting prescription-strength omega-3s in this group is reasonable rather than optional.

When to call your prescriber rather than wait

• Fasting glucose readings shift by more than roughly 20 mg/dL from your stable personal baseline on two or more consecutive days after starting or changing an omega-3 dose.
• Hypoglycemic episodes become more frequent after starting omega-3 supplementation.
• Unexplained bruising, prolonged bleeding from minor cuts, or blood in stool or urine develops.
• You are considering adding aspirin, an NSAID, or an anticoagulant to a regimen that already includes insulin and omega-3 supplementation.
• You have symptoms of a hypoglycemic emergency (confusion, loss of consciousness, seizure), this needs urgent care, not a scheduled follow-up.

What is established, what is plausible, and what is not known

Established: insulin degludec and omega-3 fatty acids are cleared and absorbed through separate pathways, so a pharmacokinetic interaction is not expected. No major diabetes guideline reviewed for this article lists omega-3 supplementation as contraindicated with insulin degludec or any other basal insulin.

Plausible but not firmly quantified: modern moderate-dose omega-3 supplementation has a small and inconsistent effect on glucose control in people with diabetes, and higher doses carry an additive antiplatelet effect on top of insulin's own antiplatelet activity. The direction of these effects is reasonably well supported in general diabetes and cardiovascular literature; the precise magnitude specific to insulin degludec users has not been established because no dedicated study of that combination was identified.

Not established: any specific numeric interaction risk (a defined percentage increase in bleeding risk or a defined mg/dL glucose shift) attributable to combining these two agents. Readers should treat any such specific number encountered elsewhere with caution unless it traces to a verifiable primary source.

Practical framework

Step 1: Identify the dose. OTC 1 to 2 g/day EPA+DHA is the lowest-concern range. Prescription-strength 4 g/day products require prescriber-level oversight because they are prescription drugs with their own monitoring requirements.

Step 2: Review the full medication list. Anticoagulants, antiplatelet drugs, and NSAIDs change the risk calculus for higher-dose omega-3s. Tresiba by itself is not a reason to avoid omega-3 supplementation.

Step 3: Set a monitoring anchor. A baseline fasting glucose (and lipid panel, if triglycerides are the reason for supplementing) before starting, followed by a recheck after a few weeks, gives an objective way to catch the uncommon patient who shows a real shift rather than relying on how they feel.

References

The following general sources informed this article. Several precise citations from earlier drafts of this topic could not be verified against the primary literature and have been described in general terms above rather than attached to specific study identifiers; a qualified reviewer should confirm exact effect sizes before they appear in patient-facing content.

• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019. https://www.nejm.org/doi/10.1056/NEJMoa1812792
• American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes (current edition). https://diabetesjournals.org/care/care-current-issue
• U.S. Food and Drug Administration. Drug label and prescribing information database. https://www.fda.gov

This article is intended for general education and does not replace individualized medical advice. It is pending qualified clinical review. Dosing, monitoring plans, and management of any bleeding or glucose concerns should be determined with your prescriber or pharmacist based on your full medication list and health history.